The increased awareness of antiviral resistance over the past decade has paralleled the development of new antiviral agents. While such resistant viral isolates are of clinical significance primarily in immunocompromised individuals, the development and transmission of such mutants have been reported in immunocompetent persons as well. As antiviral agents are increasingly utilised by the clinician, the incidence of such occurrences is likely to increase. Issues relating to mechanisms of antiviral resistance, clinical manifestations and significance of resistance, and implications for future antiviral development and utilisation are reviewed in this article. Viruses that are discussed include herpes simplex virus, varicella-zoster virus, cytomegalovirus, influenza A virus, and human immunodeficiency virus.
Introduction
The development of increasing numbers of antiviral agents over the past decade has provided the clinician with therapeutic options previously unavailable. The ability now exists to treat disease caused by herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), influenza A virus, and human immunodeficiency virus-1 (HIV-1). With the increasing utilisation of antiviral drugs, however, has come an enhanced appreciation of the development of antiviral resistance.
The antiviral agents currently licensed for use by the United States Food and Drug Administration generally inhibit steps in virus-specific replication. This is usually accomplished by the targeting of viral enzymes, thus interfering with viral nucleic acid synthesis. In general, mutations within the viral genome account for the acquisition of antiviral resistance. Single non-lethal nucleotide mutations often result in critical amino acid substitutions in a viral protein. Antiviral drug pressure can select for the emergence of resistant viral isolates by conferring a survival advantage to those subpopulations that are relatively less susceptible to the antiviral agent. Alternatively, spontaneous mutations may arise during drug exposure. The biological consequences of such viral mutations can include alterations in viral pathogenicity, transmissibility, and genetic stability. At the present time, however, the degree to which most resistant viruses are impaired in these vital functions is incompletely understood.
Disease caused by drug resistant viruses occurs most frequently in immunocompromised patients. This finding highlights the importance of an intact host defence system for recovery from virtually all viral infections. Immunosuppression enhances the opportunity for viral replication to occur at high levels for extended periods of time. In turn, this provides a suitable environment for the emergence of resistant isolates, especially in the presence of antiviral agents. Circumstances which favour the selection of resistant isolates include high viral replicative loads, high intrinsic mutation rates and prolonged drug exposure. Clinical manifestations suggesting the emergence of antiviral resistance include failure to resolve disease despite adequate antiviral therapy, as well as inability to suppress or eradicate viral replication in the host.
Development of antiviral resistance will surely increase in frequency and significance as antiviral agents are utilised more widely. Issues relating to mechanisms of antiviral resistance, clinical manifestations and significance of resistance, and implications for future antiviral development and utilisation are reviewed in this article. The Table provides an overview for reference as individual viruses are discussed. An appreciation of the mechanisms of antiviral resistance will prove beneficial in developing future treatment strategies designed to minimise the emergence of antiviral resistance.
Herpes simplex virus (HSV)
The antiviral drug of choice for the treatment of HSV infections is acyclovir. Additional antiviral agents with activity against HSV include vidarabine, foscarnet, sorivudine, penciclovir, and famciclovir, (the prodrug of penciclovir). Acyclovir is converted by virus-encoded thymidine kinase (TK) to its monophosphate derivative, an event that does not occur to any substantial extent in uninfected cells (Fyfe et al., 1978; Elion, 1983) . Subsequent diphosphorylation and triphosphorylation are catalysed by cellular enzymes, resulting in acyclovir triphosphate concentrations that are 40-100 times higher in HSV infected cells than in uninfected cells (Elion, 1982; Whitley & Gnann, 1992) . Acyclovir triphosphate inhibits viral DNA synthesis by competing with deoxyguanosine triphosphate as a substrate for viral DNA polymerase (Derse et al., 1981) . Because acyclovir-triphosphate lacks the 3'-hydroxyl group required to elongate the DNA chain, the synthesis of viral DNA is terminated and the viral DNA polymerase is functionally inactivated (Furman, St. Clair, & Spector, 1984; Reardon & Spector, 1989) . In addition, the viral polymerase exhibits a 10-to 30-fold greater affinity for acyclovir-triphosphate than does cellular DNA polymerase, resulting in little incorporation of acyclovir into cellular DNA (Furman et al., 1979) . This higher concentration of the active triphosphate metabolite in infected cells plus the affinity for viral polymerases result in the very low toxicity of acyclovir for normal host cells.
Acyclovir resistance is mediated by mutations within either the HSV TK gene or the viral DNA polymerase gene. Viral isolates in which resistance is conferred by TK mutations are categorised both by the extent of TK activity present and by TK substrate specificity. In addition to wild type (TK + ) virus, three phenotypes of acyclovir resistant TK mutants have been described. Thymidine kinase-negative (TK -) mutants are completely devoid of TK activity. Thymidine kinase-partial (TKp) variants are very low producers of TK, having only 1-15% of normal TK activity; this degree of decrease in TK impairs their ability to phosphorylate acyclovir effectively. The third category of TK mutants are the TK-altered (TKa) viruses; they are unable to phosphorylate acyclovir but can still phosphorylate thymidine. Owing to variability among the current assays used to detect viral TK activity, TKp mutants can be misidentified as TK-mutants. In addition, some overlap exists between TKa and TKp mutants. Despite these potential difficulties in phenotypic identification, it remains useful to consider TK mutants with respect to extent of viral TK expression. The spectrum of TK mutations conferring acyclovir resistance has largely been defined from analysis of laboratory-derived isolates.
As such, a distinction should be made between resistant variants generated in the laboratory and those acyclovir-resistant isolates obtained from patients in the clinical setting. As will be discussed, the vast majority of resistant clinical isolates are TK -.
Mutations within the viral DNA polymerase gene also result in acyclovir resistance (Larder, Kemp, & Darby, 1987; Gibbs et al., 1988) . All polymerase mutants analysed to date result from DNA point mutations. However, the mechanism(s) by which such mutations confer resistance to acyclovir is unknown. Possibilities include:
(1) alterations in the competitive inhibition between acyclovir-triphosphate and deoxyguanosine-triphosphate; (2) decreased incorporation of acyclovir-triphosphate into the growing DNA chain; and (3) altered polymerase stability, resulting in decreased likelihood of enzyme inactivation following integration of the acyclovirtriphosphate molecule into the growing nucleic acid chain. Virtually all acyclovir resistant polymerase mutants identified to date have been generated in the laboratory, with only two such variants having been recovered from patients in the clinical setting Sacks et al., 1989) . This suggests that HSV can more readily evade ACV suppression by means of mutations which reduce or alter TK function.
While mutations conferring a TK -or a TKp phenotype can occur virtually anywhere within the 1.3 kilobase (Kb) TK gene, preliminary data suggest that these mutations may (Hwang & Chen, 1995) . To date, only a few distinct mutations conferring a TKa phenotype have been identified (Darby, Larder, & Inglis, 1986; Kost et al., 1993) . More than 20 different polymerase mutations have been identified in at least six discrete regions of the polymerase gene, spanning more than 1 Kb.
Penciclovir, famciclovir, vidarabine, and foscarnet are additional antiviral agents available for the treatment of HSV. As famciclovir is rapidly deacetylated and oxidised to form penciclovir, mechanisms of antiviral resistance for these two compounds are identical. Penciclovir resistant HSV isolates with mutations in either the TK gene or the viral DNA polymerase gene can be selected by passage in vitro. Penciclovir and acyclovir resistant mutants are roughly similar with respect to both phenotypic and genotypic alterations. Mutations in the viral DNA polymerase gene confer resistance to vidarabine and/or foscarnet.
The first report of an HSV isolate resistant to acyclovir occurred in 1982 (Crumpacker et al., 1982) , the same year that acyclovir received approval from the United States Food and Drug Administration. Additional isolated cases were reported between 1982 and 1989 (Burns et al., 1982; Sibrack et al., 1982; Barry et al., 1985) . In 1989, twelve AIDS patients with acyclovir resistant HSV isolates were described, foreshadowing the increasing recognition of resistant viruses among immunocompromised individuals (Erlich et al., 1989) . Most of the clinical isolates identified to date are TK-mutants Hill, Hunter, & Ellis, 1991) . These TK-viruses frequently produce a truncated, nonfunctional TK enzyme (Chatis & Crumpacker, 1991) . Point mutations resulting in amino acid substitutions have also been described in TK-clinical isolates. Isolates with point mutations which confer a TKa phenotype have been isolated from patients as well (Kost et al., 1993) . As stated above, only two clinical isolates with acyclovir resistance conferred by a DNA polymerase mutation have been identified Sacks et al., 1989) . It is likely that TKp isolates will also be found to cause clinical disease as methods of detecting low concentrations of TK are improved.
Acyclovir resistant HSV has been reported to cause meningitis, oesophagitis, and pneumonia in immunocompromised patients (Sacks et al., 1989; Ljungman et al., 1990) .
Herpes simplex virus isolates demonstrate acyclovir resistance in approximately 5% of transplant patients and patients with AIDS (Englund et al., 1990; Chatis & Crumpacker, 1992) . In contrast, just one case of recurrent genital HSV disease caused by an acyclovir resistant virus has been reported among immunocompetent individuals (Kost et al., 1993) . In addition, a single case of neonatal disease caused by an acyclovir resistant isolate has been reported (Nyquist et al., 1994) . Foscarnet resistant clinical isolates have been reported in HIV infected patients (Safrin et al., 1994) ; mechanisms of resistance are being characterised at this time. This distribution of resistant mutants emphasises the importance of an intact immune system in viral infections, as discussed earlier.
Patients with documented acyclovir resistant HSV disease have demonstrated healing of mucocutaneous lesions following a change of therapy to foscarnet . However, treatment with vidarabine has not proved beneficial, even when the isolate demonstrates in-vitro susceptibility to both foscarnet and vidarabine (Safrin et al., 199la) . Patients with acyclovir resistant isolates who fail to response to vidarabine have had healing of lesions upon institution of foscarnet (Safrin et al., 199la) .
Cytomegalovirus (CMV)
Both ganciclovir and foscarnet are effective for the treatment of CMV disease. As with HSV, foscarnet directly inhibits the CMV DNA polymerase by blocking the pyrophosphate binding site and preventing cleavage of pyrophosphate from deoxynucleotide triphosphates. Ganciclovir, on the other hand, is converted to its monophosphate form by the phosphotransferase encoded by the CMV UL97 gene (Littler, Stuart, & Chee, 1992; Sullivan et al., 1992) . Cellular enzymes subsequently convert GCV-monophosphate to the active triphosphate form. While the UL97 gene product appears to be an essential viral enzyme, the exact role that UL97 phosphotransferase plays in CMV replication or pathogenesis is unknown at this time.
Ganciclovir resistance is mediated by mutations in either the UL97 gene or the CMV DNA polymerase gene (Lurain et al., 1992; Sullivan et al., 1993; Lurain, Penland & Thompson, 1994a) . Cytomegalovirus isolates with mutations in the UL97 open reading frame compose the predominant phenotype of GCV resistant isolates (Stanat et al., 1991; Chou et al., 1993; Wolf et al., 1993; Hanson et al., 1994; Lurain, Spafford & Thompson, 19946; Baldanti et al., 1995) . Such isolates have impaired capacity to phosphorylate ganciclovir to its monophosphate form, resulting in diminished concentrations of the active ganciclovir-triphosphate. Among ganciclovir resistant clinical and laboratory isolates, little sequence or amino acid diversity exists in the UL97 gene or its protein product (Chou et al., 1995) . Mutations in UL97 which confer ganciclovir resistance are clustered in two highly conserved regions: subdomain VI, which encompasses an ATP binding site and may play a role in substrate recognition; and subdomain IX, which may be involved in substrate-inhibitor binding. Overall, 85% of ganciclovir resistant mutants have point mutations or, rarely, deletions affecting the methionine at codon 460, the alanine at codon 594, or the leucine at codon 595 (Sullivan et al., 1992; Baldanti et al., 1995; Chou et al., 1995; Wolf et al., 1995) . Because of this high degree of UL97 sequence conservation among clinical strains and the restricted number of mutations, development of a polymerase chain reaction (PCR)-based assay of CMV resistance genotypes is promising (Chou et al., 1995) .
Only a small number of ganciclovir resistant CMV isolates appear to have mutations in the DNA polymerase gene. To date, four laboratory isolates (Sullivan et al., 1993; Lurain et al., 1992) and one clinical isolate (Tatarowicz, Lurain & Thompson, 1992; Lurain et al., 1994a) have been reported. Given the very small number of CMV polymerase mutants so far identified, insufficient information exists regarding the need for or feasibility of development of rapid detection assays.
Mutations in the CMV DNA polymerase gene can also confer resistance to foscarnet (D'Aquila, Hayward & Summers, 1989; Sullivan & Coen, 1991; Tatarowicz et al., 1992) . As the use of foscarnet increases, more information will become available regarding both the frequency of polymerase mutations in foscarnet-treated patients and the specific locations of these mutations within the polymerase gene.
The prevalence of ganciclovir resistant CMV strains in AIDS patients taking ganciclovir for more than 3 months is estimated to be 7.6% . Clinical events in patients excreting such isolates suggest that the resistant strains are virulent. Recovery of resistant virus from patients receiving ganciclovir for treatment of CMV retinitis is associated with progression of retinal disease (Erice et al., 1989) . However, clinical deterioration has also been observed in patients who are excreting ganciclovir sensitive strains.
Cytomegalovirus cultures in patients with CMV retinitis are frequently negative, a fact that complicates the determination of whether ganciclovir resistant strains are present. Foscarnet has been used successfully to treat ganciclovir resistant CMV retinitis in patients with AIDS (Jacobson et al., 1991) .
Varicella-zoster virus (VZV)
Although the use of the penciclovir prodrug, famciclovir, for the treatment of VZV disease has increased in the past year, acyclovir remains the drug of choice for the treatment of VZV infection at this time. In a manner analogous to HSV, the VZV TK is responsible for the initial phosphorylation of acyclovir, with cellular enzymes subsequently converting the acyclovir-monophosphate to the active triphosphate compound. By competing with dGTP, acyclovir-triphosphate inactivates the VZV DNA polymerase, resulting in premature termination of the growing viral DNA chain.
As is the case with HSV, acyclovir resistance in VZV is predominantly conferred by mutations in the viral TK gene. Such mutants are categorized both by the extent of TK activity present and by TK substrate specificity. Thymidine kinase-negative mutants are devoid of TK activity and cannot phosphorylate thymidine, deoxycytidine, or acyclovir. Such isolates usually produce truncated TK proteins due to a stop codon in the gene. Viral mutants that encode an altered TK are unable to phosphorylate acyclovir or deoxycytidine but can still phosphorylate thymidine (Talarico, Phelps, & Biron, 1993; Boivin et al., 1994) . This altered substrate specificity is usually due to a point mutation in the TK gene, although truncated mutations at the carboxyterminal end have also been reported in this phenotype.
Both laboratory (Mori et al., 1988; Sawyer et al., 1988; Lacey et al., 1991; Suzutani et al., 1992) and clinical (Roberts et al., 1991; Talarico et al., 1993; Boivin et al., 1994) isolates with acyclovir resistance conferred by mutations in the viral TK have been described. Of the laboratory isolates, eight point mutations have been reported, while among clinical isolates ten point mutations have been described. In both cases, the point mutations occur throughout the VZV TK gene. Frameshift mutations which result in truncated TK gene products have been generated in vitro, and twelve clinical specimens with frameshift mutations yielding truncated TKs have been described Boivin et al., 1994) . Of these 12 mutants, four contain a stop codon at amino acid 231, making this the most common site of mutation in the acyclovir resistant VZV isolates identified to date.
As with HSV, mutations in the VZV DNA polymerase can confer acyclovir resistance. Most of these isolates have been generated in the laboratory, and DNA polymerase mutants are believed to occur only very rarely in the clinical setting.
All clinical cases of acyclovir resistant VZV disease have occurred in AIDS patients receiving prolonged oral acyclovir therapy (Pahwa et al., 1988; Sawyer et al., 1988; Hoppenjans et al., 1990; Jacobson et al., 1990; Linnemann et al., 1990; Safrin et al., 19916; Talarico et al., 1993; Boivin el al., 1994) . All of these patients have had CD4 counts below 100 x 10*/L, with most being under 25 x 10*/L. Patients with acyclovir resistant VZV disease present with chronic varicella or zoster which lacks the classic features of either infection. Lesions can be hyperkeratotic or ulcerative, frequently involving multiple dermatomes. Dissemination to visceral organs does not occur. Disease course is indolent, with slow progression of widely scattered atypical lesions. Viral isolation from lesions is difficult, and excisional biopsy is often required for definitive diagnosis. One should suspect an acyclovir resistant VZV infection if lesions persist or progress 7-10 days after initiation of adequate acyclovir therapy; an empirical change from acyclovir to foscarnet is then warranted .
Influenza
The antiviral agents of choice for the treatment of influenza A virus infections are amantadine and rimantadine. Both of these drugs target the viral M2 protein, a pH-activated transmembrane ion channel (Pinto, Holsinger & Lamb, 1992; Lamb, Holsinger & Pinto, 1994; Tosteson et al., 1994; Wang, Lamb & Pinto, 1994) . The M2 channel permits ions to enter the virion during the process of uncoating; this destabilises protein-protein bonds and allows transport of the viral DNA into the nucleus . Additionally, the M2 channel ion flux modulates the pH of intracellular compartments, particularly the Golgi apparatus (Hay, 1992; . This compartmental change in pH stabilises the influenza A virus hemagglutinin (HA) during intracellular transport in some species Takeuchi, Shaughnessy & Lamb, 1994; Grambas, Bennett & Hay, 1992) . Both amantadine and rimantadine interfere with these M2 channel activities (Pinto et al., 1992; Wang et al., 1993) .
Mutations in the transmembrane domain of the M2 protein confer resistance to amantadine and rimantadine. The amino acid sequence of the transmembrane region is highly conserved among all human, swine, equine, and avian strains of influenza A virus (Hay, 1992) . Amantadine and rimantadine resistant influenza A clinical isolates contain single amino acid substitutions at one of five residues (amino acids 26, 27, 30, 31, and 34) of the transmembrane domain of the M2 protein (Belshe et al., 1988) . This spectrum of mutations is also noted among in-vitro isolates passaged in the presence of either antiviral agent (Hay, 1992) . Amantadine and rimantadine appear to demonstrate identical pharmacodynamics with respect to M2 channel activity (Wang et al., 1993) .
In animal models, amantadine and rimantadine resistant influenza A isolates: (1) emerge rapidly during antiviral therapy; (2) are genetically stable; (3) can be transmitted; and (4) are pathogenic in contacts (Beard, Brugh & Webster, 1987; Bean, Threlkeld & Webster, 1989; Sweet et al., 1991) . Clinical studies of antiviral therapy in influenza A disease have demonstrated that resistance to amantadine and rimantadine emerges rapidly in humans as well (Hall et al., 1987; Belshe et al., 1989; Hayden et al., 1989; Hayden et al., 1991) . Within 3-5 days of initiation of therapy, up to 30% of children and adults shed resistant virus (Hall et al., 1987; Belshe et al., 1989; Hayden et al., 1991) . The shedding of resistant mutants has not been associated with clinical deterioration, although patients shedding resistant virus may have slightly prolonged illness compared with treated patients who are not shedding resistant virus . Duration of shedding of resistant virus is usually less than 10 days from the initiation of treatment (Hall et al., 1987; Hayden et al., 1989) . Risk factors for the shedding of resistant virus have yet to be identified.
Amantadine and rimantadine both appear to be effective for postexposure prophylaxis in families when index cases are not treated (Hayden, 1994) . However, trials in which the index case is also treated have found postexposure prophylaxis to be only marginally effective, possibly because of spread of resistant viruses within the household (Hayden et al., 1989) . Studies of antiviral treatment and prophylaxis in nursing homes D. \V. KimberUn and R. J. Whitley have found that amantadine therapy without isolation of treated index cases is associated with prophylaxis failures (Mast et al., 1991) . Resistant viruses recovered from prophylaxis failures cause illness that is as severe as that caused by wild-type virus (Hayden et al., 1989; Mast et al., 1991) .
Human immunodeficiency virus-1 (HIV-1)
The three major classes of inhibitors of HIV-1 replication are: (1) nucleoside analogue inhibitors of the viral reverse transcriptase (RT) enzyme; (2) non-nucleoside inhibitors of the viral RT enzyme; and (3) inhibitors of the viral protease. All antiviral drugs currently approved for treatment of HIV-1 infection belong to the nucleoside analogue class of inhibitors. These include zidovudine, 2',3'-dideoxyinosine (ddl, didanosine), 2',3'-dideoxycytosine (ddC, zalcitabine), and 2',3'-didehydro-2',3'-dideoxythymidine (D4T, stavudine).
Understanding of the in-vivo viral dynamics of HIV-1 has increased dramatically in recent months. The continuous in-vivo replication of HIV-1 and the rapid turnover of infected cells is elegantly detailed in two pioneering reports (Ho et al., 1995; Wei et al., 1995) . In addition, the selective effect of antiviral therapy is clearly confirmed by the finding that almost complete replacement of wild-type virus by drug resistant isolates occurs after only 2-4 weeks of antiviral therapy (Wei et al., 1995) . As stressed earlier, high viral replicative loads and intrinsic mutation rates predispose to the emergence of antiviral resistance, especially during drug exposure.
The nucleoside analogue RT inhibitors act by mediating premature termination of nascent viral DNA synthesis. Resistant viral variants have been isolated both in vitro and in vivo for all of the compounds studied to date, although the resistance to zalcitabine and stavudine appears to be of borderline magnitude and significance (Larder & Kemp, 1989; Larder, Coates & Kemp, 1991; St. Clair, Martin & Tudor-Williams, 1991; Fitzgibbon et al., 1992; Gu et al., 1992; Kellam, Boucher & Larder, 1992; Gao et al., 1993; Schinazi et al., 1993; Slade et al., 1993; Tisdale et al., 1993; Gu et al., 19940,6; Lacey & Larder, 1994; Tisdale et al., 1994a; Zhang et al., 1994) . Loss of susceptibility appears to be due to RT amino acid substitutions either near the enzyme's active site or at the finger domain of the p66 subunit. Such mutations appear to affect the enzyme's interaction with the primer and template, decreasing the ability of the enzyme-template-primer complex to recognise the inhibitor. Different combinations of substitutions result in varying degrees of viral resistance (Larder & Kemp, 1989) . Certain substitutions or combinations of substitutions can confer resistance to multiple inhibitors. Zidovudine resistance was initially described in clinical isolates in 1989 (Larder, Darby & Richman, 1989) . Early reports showed that patients with isolates that were highly resistant to zidovudine experienced no sudden increases in p24 antigen or abrupt clinical deteriorations. Subsequent studies have attempted to address more fully the clinical consequences of zidovudine resistance. These efforts have culminated in the finding that, after controlling for other predictors of progression, high-level zidovudine resistance predicts accelerated disease progression or death in patients with advanced HIV-1 disease (D'Aquila et al., 1995) . Furthermore, high-level zidovudine resistance is associated with an increased risk for death even when monotherapy is changed from zidovudine to didanosine (D'Aquila et al., 1995) . Since zidovudine sensitive and resistant viruses are equally susceptible to ddl, there is no obvious explanation for this observation. Clearly, aspects of the interactions between the host and the zidovudine resistant virus are incompletely understood.
Zidovudine therapy is associated with changes in the RT gene at codons 41, 67, 70, 215, and 219 (Larder & Kemp, 1989; Larder, Coates, & Kemp, 1991; Kellam, Boucher & Larder, 1992) . Of these, mutations at codon 70 are usually the first to be detected following initiation of zidovudine therapy Loveday et al., 1995) . Several phases of zidovudine action and resistance have been proposed (Loveday et al., 1995) : (1) in Phase I, an initial decline in HIV RNA concentrations occurs following institution of zidovudine therapy, marking the period of maximal drug efficacy; (2) during the following weeks, RNA concentrations return toward baseline independently of the detection of genotypic zidovudine resistance (Phase II); (3) in Phase III, RNA concentrations remain at approximately 50% of baseline for a period of months, with a gradual upward trend that possibly represents emerging antiviral resistance; (4) a rebound to baseline occurs in Phase IV following cessation of zidovudine therapy. Although the full clinical relevance of these genotypic mutations is incompletely understood, such mutants may have a selective advantage over wild-type virus (Loveday et al., 1995) .
The non-nucleoside RT inhibitors (NNRTIs) are a structurally diverse group of compounds that all bind to the same site on the HIV-1 RT. Despite the variable structure of these agents, they are functionally similar. Upon binding to a small pocket located proximal to the RT's active site, the compounds appear to cause premature dissociation of the enzyme-template-primer complex. Resistant viral variants have been isolated both in vitro and in vivo for all of the NNRTIs studied to date (Nunberg et al., 1991; Richman et al., 1991; Larder, 1992; Mellors et al., 1992; Vasudevachari et al., 1992; Balzarini et al., \993b,c,d,e; Balzarini, Karlsson, & De Clercq, 1993a; Byrnes et al., 1993a,*; de Bethune et al., 1993; Demeter et al., 1993; Dueweke et al., 1993; Kleim et al., 1993; Maas et al., 1993; Mellors et al., 1993; Richman, 1993; Saag et al., 1993; Balzarini ef al., 1994; Hong-Nguyen et al., 1994; Richman etal., 1994; Shaw et al., 1994; Vandamme et al., 1994) . Amino acid substitutions which confer resistance to the NNRTI compounds are located within the inhibitor binding pocket and probably alter the RT's ability to interact with the drug. As with the nucleoside RT inhibitors, different amino acid substitutions confer varying degrees of antiviral resistance. Isolates with multiple amino acid substitutions may exhibit resistance to several of the NNRTIs.
The clinical consequences of resistance to NNRTIs are much more straightforward than for zidovudine resistance. As seen in the in-vitro studies, rapid selection of NNRTI resistant isolates occurs in vivo as well (Saag et al., 1993; Richman et al., 1994 ). An initial reduction in p24 antigen concentrations and increase in CD4 cell counts within 1 or 2 weeks is followed by a loss of these responses associated with the emergence of the drug resistance phenotype. Combination trials have shown that the emergence of NNRTI resistant virus is not impeded by the concurrent administration of zidovudine Cheeseman et al., 1995) . Despite these apparent clinical weaknesses, preliminary data suggest that some patients given high doses of nevirapine (400 mg daily) have sustained antiviral activity as measured by reduction in concentrations of p24 antigen and serum HIV RNA .
The protease inhibitors (Pis) interfere with the cleavage of viral polypeptides during the process of virion maturation, resulting in production of noninfectious, immature viral particles. All Pis described to date bind to the active site of the HIV-1 protease. Most of the PI resistant viral mutants have been isolated in vitro, although a few in-vivo variants have been reported as well (Otto et al., 1993; el-Farrash et al., 1994; Emini et al., 1994; Ho et al., 1994; Jacobsen et al., 1994; Kaplan et al., 1994; Kempf et al., 1994; Lamarre et al., 1994; Maschera et al., 1994; Partaledis, Yamaguchi & Byrn, 1994; Pillay et al., 1994; Potts et al., 1994; Rose et al., 1994; Swanstrom et al., 1994; Tisdale et al., 19946) . Preliminary analysis of such mutants suggests that certain amino acid substitutions are associated with loss of PI susceptibility. Amino acid substitutions can occur at residues that clearly interact with the PI. Other substitutions, however, are located at amino acid residues that do not appear to be directly involved in the interaction between the PI and the protease enzyme. The phenotypic influences of individual substitutions await the results of confirmatory genetic studies.
Resistance to the Pis is being recognised in the clinical setting as these compounds move into controlled trials Jacobsen et al., 1994) . At this time however, clinical data on resistance to Pis are very limited. Characterisation of resistance mechanisms from clinical HIV isolates undoubtedly will grow as these agents are used in additional clinical studies.
Conclusions
With the increasing utilisation of antiviral agents in patient management, antiviral resistance has moved from the realm of the laboratory to the clinical setting. Currently, resistant viruses are isolated primarily from immunocompromised persons taking antiviral drugs for prolonged periods of time. Reports of such mutants causing disease in immunocompetent individuals are becoming increasingly common, however. As such, development of antiviral resistance will surely increase in frequency and significance in the future. Despite this likelihood, the focus of ongoing research efforts should be the development of new and unique antiviral drugs to supplement the limited number of agents currently available. In addition, rapid techniques to detect resistant clinical isolates should be developed and made available to clinicians. As detection of antiviral resistance improves and new treatment options are introduced, additional strategies to combat the emergence of antiviral resistance can be developed and existing strategies refined.
